Drug Trial Radar · NCT01462942
Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination
Last checked: Nov 19, 2026Latest source record: Feb 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,443
Actual
Start
Oct 2011
Primary completion
Jan 2013
Study completion Jan 2013
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 1, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective is to provide data supporting the use of LAS40464 as an efficacious and safe maintenance bronchodilator treatment of patients with Chronic Obstructive Pulmonary Disease (COPD).
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Aclidinium Bromide/Formoterol FumarateDrug
Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day
Aclidinium Bromide/Formoterol FumarateDrug
Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day
Aclidinium BromideDrug
Inhaled Aclidinium 400 μg, twice per day
PlaceboDrug
Inhaled dose-matched placebo, twice per day
Formoterol FumarateDrug
Inhaled Formoterol 12 μg, twice per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1)Time frame: Baseline and Week 24
- Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)Time frame: Baseline and Week 24
Locations
197 sites in 22 countries. Site status is shown where the registry gives one.
Almirall Investigational Site #2
Graz, Austria
Almirall Investigational Site #3
Salzburg, Austria
Almirall Investigational Site #3
Edegem, Belgium
Almirall Investigational Site #2
Genk, Belgium
Almirall Investigational Site #6
Rousse, Bulgaria
Almirall Investigational Site #10
Sevlievo, Bulgaria
Almirall Investigational Site #8
Sofia, Bulgaria
Almirall Investigational Site #2
Sofia, Bulgaria
Almirall Investigational Site #11
Sofia, Bulgaria
Almirall Investigational Site #2
Zagreb, Croatia
Almirall Investigational Site #4
Zagreb, Croatia
Almirall Investigational Site #8
Brno, Czechia
Almirall Investigational Site #3
Jindřichův Hradec, Czechia
Almirall Investigational Site #10
Karlovy Vary, Czechia
Almirall Investigational Site #9
Liberec, Czechia
Almirall Investigational Site #16
Ostrava Hrabuvka, Czechia
Almirall Investigational Site #2
Prague, Czechia
Almirall Investigational Site #12
Prague, Czechia
Almirall Investigational Site #15
Prague, Czechia
Almirall Investigational Site #14
Prague, Czechia
Almirall Investigational Site #6
Praha 5 - Radotin, Czechia
Almirall Investigational Site #11
Strakonice, Czechia
Almirall Investigational Site #1
Tábor, Czechia
Almirall Investigational Site #4
Hillerød, Denmark
Almirall Investigational Site #1
København NV, Denmark
Almirall Investigational Site #5
Odense, Denmark
Almirall Investigational Site #2
Silkeborg, Denmark
Almirall Investigational Site #7
Espoo, Finland
Almirall Investigational Site #8
Jyväskylä, Finland
Almirall Investigational Site #1
Tampere, Finland
Almirall Investigational Site #6
Tampere, Finland
Almirall Investigational Site #3
Turku, Finland
Almirall Investigational Site #6
Lille, France
Almirall Investigational Site #10
Marseille, France
Almirall Investigational Site #11
Montpellier, France
Almirall Investigational Site #1
Pessac, France
Almirall Investigational Site #3
Rennes, France
Almirall Investigational Site #8
Toulouse, France
Almirall Investigational Site #12
Vieux-Condé, France
Almirall Investigational Site #2
Berlin, Germany
Showing 40 of 197 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.